SM
RGNX icon

SG3 Management’s Regenxbio RGNX Stock Holding History

SG3 Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$84K – 1244
2021
Q3 		$84K Sell
2,000
-13,000
-87% -$468K ﹤0.01% 881
2021
Q2 		$583K Sell
15,000
-15,000
-50% -$536K 0.02% 625
2021
Q1 		$1.02M Buy
+30,000
New +$1.28M 0.03% 602

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG3 Management's RGNX Position: Q2 2021 in Review

SG3 Management sold out of Regenxbio (RGNX) in Q2 2021, closing a stake of 15,000 shares — an estimated $536K sold.

SG3 Management first reported a position in RGNX in Q1 2019 and held it in 2 quarters. The position peaked at $512K in Q1 2021. 172 funds tracked by Wall St. Rank hold RGNX as of Q2 2021.

  • SG3 Management reported no remaining Regenxbio position as of Q2 2021 after selling out during the quarter.
  • SG3 Management sold 15,000 Regenxbio shares in Q2 2021, an estimated $536K.
  • SG3 Management first reported a position in Regenxbio in Q1 2019 and held it in 2 quarters.
  • SG3 Management's Regenxbio position peaked at $512K in Q1 2021.
  • 172 funds tracked by Wall St. Rank held Regenxbio as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.